Session » Systemic Sclerosis & Related Disorders – Clinical Poster I

Date: Saturday, November 16, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 0694

A Unified Vascular Phenotype Score Identifies Systemic Sclerosis Endotypes and Predicts Prognostic Outcomes: Results from the EUSTAR Database

10:30AM-12:30PM: Abstract Number: 0702

AISA 021, a Novel Calcium Channel Antagonist in Development for Raynaud’s & Systemic Sclerosis, Has Antagonistic Activity at Sodium Channel Targets for Pain Relief and Treats Scleroderma Pain Better Than Current Calcium Channel Blockers in a Phase 2A Study

10:30AM-12:30PM: Abstract Number: 0713

Anti-muscarinic 3 Antibodies in SSc Associate with a More Significant GI and Extraintestinal Clinical Phenotype

10:30AM-12:30PM: Abstract Number: 0689

Arrhythmic Burden, Myocardial Markers, and Long-term Survival in Distinct Cardiac Magnetic Resonance Subsets of Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 0697

Association of ANCA-Associated Vasculitis and Development of SSc and SSc-Associated Antibodies: Impact of Pulmonary Arterial Hypertension

10:30AM-12:30PM: Abstract Number: 0698

Association of Systemic Sclerosis with ANCA-Associated Vasculitis and Large Vessel Vasculitis: Impact of Pulmonary Arterial Hypertension

10:30AM-12:30PM: Abstract Number: 0693

Behind the Bronchiectasis in Systemic Sclerosis. Prevalence and Risk Factors

10:30AM-12:30PM: Abstract Number: 0690

Can Immunosuppression or Vasodilation Prevent the Onset of Interstitial Lung Disease in Systemic Sclerosis? An Association Analysis from the EUSTAR Database

10:30AM-12:30PM: Abstract Number: 0699

Cardiac Biomarkers for Predicting Cardiopulmonary Toxicity of Autologous Haematopoietic Stem Cell Transplantation for Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 0680

Clinical Correlates of Physical and Mental Health in Early Systemic Sclerosis: Data from the Collaborative National Quality and Efficacy (CONQUER) Registry

10:30AM-12:30PM: Abstract Number: 0679

Comparing Raynaud’s Phenomenon Measurement Tools: Results of the Optimizing Raynaud Phenomenon Outcome Measures in Systemic Sclerosis (ROSS) Study

10:30AM-12:30PM: Abstract Number: 0707

Comprehensive Skin Assessment in Systemic Sclerosis Using Spatial Frequency Domain Imaging (SFDI)

10:30AM-12:30PM: Abstract Number: 0701

Diagnostic Performances of Vascular Biomarkers Soluble Fms-like Tyrosine Kinase (sFlt-1) and Placental Growth Factor (PlGF) in Scleroderma Renal Crisis: A Case Control Study

10:30AM-12:30PM: Abstract Number: 0712

Efficacy of Sacubitril/Valsartan in Patients with Systemic Sclerosis and Heart Failure: A Retrospective Analysis

10:30AM-12:30PM: Abstract Number: 0692

Evaluation of the New Criteria for Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 0710

High S100A4 Levels Associate with Inflammation and Vasculopathy in Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 0705

Identification of Risk Factors for Incident Cardiomyopathy in Patients with Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 0681

Influence of Occupational Exposure to Pollutants on Clinical and Serological Phenotypes in Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 0685

KL-6 and IL-18 Biomarkers in Systemic Sclerosis-associated Interstitial Lung Disease: Enhancing Prognostic Insights into Early Detection, Progression, Lung Volume Changes,and Mortality Risk

10:30AM-12:30PM: Abstract Number: 0709

Linear Combination of Principal Components Achieves Top Performance in Identifying Rheumatologist-Diagnosed Systemic Sclerosis from Electronic Health Records

10:30AM-12:30PM: Abstract Number: 0711

Molecular Signatures in the Skin as Predictors of Longitudinal Clinical Trajectories in Patients with Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 0696

MRI DAVIX Index Is an Imaging Biomarker for Endothelial Damage of Systemic Sclerosis Digital Ulcers

10:30AM-12:30PM: Abstract Number: 0688

Mycophenolate Mofetil Treatment in Limited Cutaneous Systemic Sclerosis Reduces the Risk of Vascular Complication Leading to Treatment Escalation: Emulation of a Target Trial Using Time-dependent Propensity Score-matching

10:30AM-12:30PM: Abstract Number: 0708

Outcomes of Intermittent Intravenous Steroid Use During Infusion Therapy in Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 0678

Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually

10:30AM-12:30PM: Abstract Number: 0687

Patterns of Disease Progression in Early Systemic Sclerosis Patients with Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 0677

Patterns of Raynaud’s Phenomenon Management in Patients with Systemic Sclerosis: A Real-World Data from Community-Based Practices in the United States

10:30AM-12:30PM: Abstract Number: 0691

Predictors of Response and Long-term Efficacy and Safety of Nintedanib in Systemic Sclerosis-Interstitial Lung Disease: Data from an Italian Multicentre Study

10:30AM-12:30PM: Abstract Number: 0703

Preliminary Results from the RECONNOITER Trial, a Phase 2 Study of AISA 021 in the Treatment of Secondary Raynaud’s, Primarily Due to Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 0695

Prognostic Value of Serum Type I Interferon in Predicting Morbi-Mortality Outcomes in Systemic Sclerosis: Insights from the STRIKE Basket Cohort

10:30AM-12:30PM: Abstract Number: 0683

Prognostic Value of Systemic Sclerosis-associated Primary Heart Involvement

10:30AM-12:30PM: Abstract Number: 0704

Progression of Global Longitudinal Strain and Identification of Left Ventricular Dysfunction in Systemic Sclerosis Patients

10:30AM-12:30PM: Abstract Number: 0700

Prospective Evaluation of Capillaroscopy in Healthy Children

10:30AM-12:30PM: Abstract Number: 0682

Results from Outcomes Selection and Development of a Patient-reported Outcome Measure for a Combined Response Index for Limited Cutaneous SSc: The CRISTAL Project

10:30AM-12:30PM: Abstract Number: 0706

Single Center Prospective Cohort of Systemic Sclerosis Patients Who Are At-Risk for Pulmonary Hypertension

10:30AM-12:30PM: Abstract Number: 0684

The Diagnostic Accuracy of Ultrasound for Low Muscle Mass in Women with Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 0686

The Role of Inflammation in Systemic Sclerosis: CRP-Associated Phenotypes and Prognostic Implications

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].